Navigation Links
Spanish researchers link cancer to failures in chromosome protection for the first time
Date:3/19/2013

A study published today in the journal Nature Genetics explores a new mechanism that may contribute to the development of several tumours, including Chronic Lymphocytic Leukaemia, a type of cancer that affects more than a thousand new patients in Spain each year.

This work, led by researchers Carlos Lpez-Otn, from the University Institute of Oncology at the University of Oviedo; Elas Campo, from the Hospital Clnic/University of Barcelona; and Mara Blasco, the Director of the Spanish National Cancer Research Centre (CNIO), represents a significant milestone for the Spanish Consortium in the study of the Chronic Lymphocytic Leukaemia Genome.

"Chronic Lymphocytic Leukaemia is the most frequent leukaemia in Western countries," says Lpez-Otn, adding that, "Once the most frequent genetic and epigenetic changes in its development have been decoded, it's necessary to discover the biochemical mechanisms altered by those changes, in order to be able to improve the diagnosis and treatment of this disease."

Thus, continuing the work from previous studies led by Campo and Lpez-Otn published in Nature and Nature Genetics over the past two years, the researchers concentrated on the mutations affecting POT1, one of the genes involved in the protection of the ends of chromosomes, the telomeres.

This is the first time that a gene with this function has appeared mutated in a human cancer. Blasco says: "We have been studying telomere biology for a long time, given that alterations in telomere maintenance are associated with cancer and ageing. Although the mechanisms used by tumour cells to alter their telomeres have been identified, POT1 mutations reveal yet another, previously unknown route."

Each chromosome has, at its extremes, in its telomeres, a protective hood made up of proteins, and POT1 is the staple that fixes it in place, joining it to the telomeric DNA. All of the mutations discovered in POT1 prevent this gene from fulfilling its function. The DNA at the end of the chromosome is therefore left without its protective cover. The study of the biochemical pathway that leads from these abnormalities to the uncontrolled growth of B lymphocytes can provide important clues for the understanding of chronic lymphocytic leukaemia and cancer in general.

ONE OF THE MOST FREQUENTLY MUTATED GENES IN LEUKAEMIA

Furthermore, after analysing the genome of 341 chronic lymphocytic leukaemia patients comparing for each case the genes from normal healthy cells with those of tumour cells, researchers have discovered that POT1 is one of the most frequently mutated genes in this illness.

Prior results from the Spanish Consortium for the study of the Chronic Lymphocytic Leukaemia Genome had already shown that more than a thousand mutations are involved in this disease, and that each patient has a unique combination of hundreds of them. One of the most unexpected findings of the Consortium's studies is the wide genetic and molecular diversity of the disease. The different mutated genes identify relatively small subgroups of patients with diverse disease characteristics. In fact, the most frequently-repeated mutations are only present in 15% of patients. Despite that, identifying them represents a great advance, because it is a step towards the goal of personalised therapies, adapted to the genetic profile of each individual tumour.

In the study published today, the researchers have found that 3.5% of patients with chronic lymphocytic leukaemia show POT1 mutations, but this figure rises to 9% in a subgroup of patients suffering from an especially aggressive form of the disease. In this way, the study identifies POT1 as one of the most important genes for this disease.

As Campo concludes, "Patients with POT1 mutations belong to the group that has the worst prognosis. Therapeutic intervention affecting this pathway could, therefore, help treat a group of patients whose clinical outcome is currently very poor."


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. FileHold Systems Announces: Spanish Language Pack for FileHold Document Management software is now a Standard Feature
2. Spanish scientists develop a pioneering technique to effectively treat mucositis
3. The Best Spanish Flashcard App for iTunes and Android are Now Available from Noyo Learning
4. Heavy Duty Alternators and Starters Expert Elreg Distributors Ltd. Meets Needs of International Market with Launch of Spanish Website
5. Researchers devise hidden dune filters to treat coastal stormwater runoff
6. Leading Canadian health researchers honored
7. Researchers propose a novel prognostic model for disease-specific survival in BCa patients
8. More parents say they wont vaccinate daughters against HPV, researchers find
9. Kessler Foundation researchers share findings in rehabilitation research at AAN meeting in San Diego
10. Mayo Clinic and Illinois researchers develop new sensor for methylated DNA
11. Researchers advance fight against biggest hidden virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Livermore, California (PRWEB) , ... December 02, 2016 ... ... business professionals, proudly announces the launch of its 60-day free trial program for ... round trip shipping make the offer a truly hassle free experience. , FlexiSpot’s ...
(Date:12/2/2016)... , ... December 02, 2016 , ... With the number ... rehabilitation of an injury, patients must find the one that works for them. When ... he created a machine that worked and decided to share it with others. , ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger Glacier ... just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste profile ... ShopRite and FoodTown stores in NJ and received rave comments from consumers. , Thanks ...
(Date:12/2/2016)... ... 02, 2016 , ... Clarify Health Solutions, Inc., the leading ... in an initial round of funding. The round was led by experienced investors ... receive far better care through the application of the best technologies from other ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite ended the ... Average edged 0.36% higher, to finish at 19,191.93; and the ... based as six out of nine sectors ended the day ... following Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ... Holdings Inc. (NASDAQ: INCR ), and La Quinta ...
Breaking Medicine Technology: